Ozempic® 0.5 mg Injection Pen — Basic Pre-injection Health Check Included
What is Ozempic®?
Ozempic® is a prescription medicine developed by the Danish pharmaceutical company Novo Nordisk. Its active ingredient is semaglutide, which belongs to a class of medicines known as GLP-1 receptor agonists.
Ozempic® may help improve insulin secretion, support more stable blood glucose control and assist with metabolic health management under medical supervision.
Ozempic® is supplied as a pre-filled injection pen and is usually administered once weekly. Since 2017, Ozempic® has been approved by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA), and is used in many regions worldwide, including Hong Kong.
A basic pre-injection health check is required before starting the programme. This includes:
- Liver function test
- Kidney function test
- Fasting blood glucose
- HbA1c
- Urinalysis
- Basic physical examination
This programme must be used under the guidance of qualified healthcare professionals and prescribed by a doctor.
If required, a nurse may assist with the first injection.
A one-to-one registered dietitian consultation service is also available to support your weight management plan.*
Ozempic® may be considered for adults who:
- Have a BMI of 30 kg/m² or above
- Have a BMI of 27 kg/m² to below 30 kg/m², with relevant metabolic or health concerns
- Have a busy urban lifestyle and find it difficult to maintain regular exercise
- Frequently experience a large appetite, snack cravings or late-night eating habits
Suitability must be assessed by a doctor based on your medical history, current health condition and treatment needs.


















